These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 17362994

  • 41. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 42. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
    Carroll WM.
    Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446
    [Abstract] [Full Text] [Related]

  • 43. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
    Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S.
    Adv Ther; 2011 Jan; 28(1):51-61. PubMed ID: 21153000
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?
    Kingwell E, Tremlett H.
    Expert Rev Neurother; 2009 Sep; 9(9):1263-5. PubMed ID: 19769440
    [No Abstract] [Full Text] [Related]

  • 48. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients.
    Putzki N, Katsarava Z, Vago S, Diener HC, Limmroth V.
    Eur Neurol; 2008 Sep; 59(3-4):136-42. PubMed ID: 18057900
    [Abstract] [Full Text] [Related]

  • 49. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT.
    Neurology; 2008 Oct 28; 71(18):1390-5. PubMed ID: 18525027
    [Abstract] [Full Text] [Related]

  • 50. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [Abstract] [Full Text] [Related]

  • 51. Immunomodulatory drug treatment in multiple sclerosis.
    Aharoni R.
    Expert Rev Neurother; 2010 Sep 25; 10(9):1423-36. PubMed ID: 20819013
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.